BLKB vs PLAB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health scores paint a concerning picture, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no Altman Z-Score available to confirm safety from distress. Despite strong operating margins and recent earnings beats, the company is unprofitable overall (negative net margin and ROE), carries an extremely high debt/equity ratio of 9.93, and shows weak liquidity. Valuation multiples like a Price/Book of 24.60 appear stretched against poor profitability, while insider selling and declining revenue further undermine confidence. The stock trades below analyst targets but faces significant structural and financial headwinds.
PLAB presents a dichotomy between a pristine balance sheet and concerning valuation/sentiment signals. While the Piotroski F-Score of 4/9 indicates stable health and the company maintains zero debt with exceptional liquidity, the stock's 157.8% one-year rally has outpaced its modest 6-8% growth rates. The current price of $45.84 is trading near its growth-based intrinsic value ($47.27) but significantly above its defensive Graham Number ($33.13). Heavy insider selling by the CEO and President, coupled with a high PEG ratio of 2.64, suggests the stock is currently overextended.
Compare Another Pair
Related Comparisons
BLKB vs PLAB: Head-to-Head Comparison
This page compares Blackbaud, Inc. (BLKB) and Photronics, Inc. (PLAB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.